Bone Cancer: From Molecular Mechanism to Treatment
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 30 January 2025 | Viewed by 340
Special Issue Editors
Interests: bone cancer; osteoarthritis; metastasis; angiogenesis
Special Issue Information
Dear Colleagues,
The exact causes of bone cancer are currently unclear. Some bone cancers are related to genetic factors, while others result from exposure to radiation or drugs used to treat other cancers. However, the causes of most bone cancers remain unknown. In recent years, significant advancements have been made in the medical field for the treatment of bone cancer. High-dose chemotherapy has improved treatment outcomes, and the application of magnetic resonance imaging (MRI) and computed tomography (CT) scans has clearly shown the specific location, extent, and degree of invasion of bone cancer. These advancements have facilitated the complete surgical removal of bone cancer, thereby significantly increasing the success rate of limb salvage surgeries and reducing the need for amputation in a small fraction of patients with bone cancer. Consequently, the five-year survival rate for primary bone cancer can reach 70% or higher when detected and treated early. Nonetheless, if the cancer is at an advanced stage or has metastasized, the five-year survival rate can drop to below 30%. Conventional chemotherapeutic agents tend to be ineffective against metastatic bone cancer due to its heightened malignancy and propensity for invasion. Therefore, there is a pressing need to identify new pre-treatment prognostic markers and develop new targeted drugs as adjuvants for chemotherapy.
Dr. Chih-Yang Lin
Dr. Syuan-Ling Lin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bone cancer
- metastasis
- angiogenesis
- targeted drugs
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.